MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 15 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Josep M. Piulats, Arun Azad, Alexander Laird, Nobuaki Matsubara, Karim Fizazi, Neal D. Shore +13 more
2024· article· en· Cancer Research· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
Dana E. Rathkopf, Guilhem Roubaud, Kim N., Shahneen Sandhu, Eleni Efstathiou, Gerhardt Attard +14 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
afffundunlabeled
Genetics of symptom remission in outpatients with COVID-19
Marie‐Pierre Dubé, Audrey Lemaçon, Amina Barhdadi, Louis‐Philippe Lemieux Perreault, Essaïd Oussaïd, Géraldine Asselin +27 more
2021· preprint· en· medRxiv· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial
J Belotte, Brunella Felicetti, Amanda Baines, Ahmed YoussefAgha, Luis Rojas‐Espaillat, Ana Godoy Ortiz +4 more
2024· article· en· Trials· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
afffundno abstractunlabeled
LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Shibani Nicum, Jonathan A. Ledermann, Linda Mileshkin, Gordon C. Jayson, C. Gourley, Agnieszka Michael +12 more
2024· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
afffundno abstractunlabeled
Unsprung traps keep PARP inhibitors effective
Peter M. Brownlee, Luc Provencher, Aaron A. Goodarzi
2022· letter· en· Nature Cell Biology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affunlabeled
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Arun Azad, Karim Fizazi, Douglas Laird, Nobuaki Matsubara, Ugo De Giorgi, Consuelo Buttigliero +9 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
3
citations

How this was built: Screen · Findings · About